Publications by authors named "E G Boichenko"
Pediatric low-hypodiploidy B-cell acute lymphoblastic leukemia (LH-ALL) with variants has been proposed to be considered a manifestation of Li-Fraumeni syndrome (LFS). However, our study demonstrates that of the majority the pathogenic variants in the TP53 gene are somatic (70.5%), and only 12.
View Article and Find Full Text PDFBlinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL.
J Immunother Cancer
June 2024
The bispecific T cell-binding antibody blinatumomab (CD19/CD3) is widely and successfully used for the treatment of children with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Here, we report the efficacy of a single course of blinatumomab instead of consolidation chemotherapy to eliminate minimal residual disease (MRD) and maintain stable MRD-negativity in children with primary BCP-ALL.Between February 2020 and November 2022, 177 children with non-high-risk BCP-ALL were enrolled in the ALL-MB 2019 pilot study (NCT04723342).
View Article and Find Full Text PDFArticle Synopsis
- The study analyzes infants with germline KMT2A-g B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving treatment under the MLL-Baby protocol, highlighting outcomes and diagnostic features.
- Out of 139 patients, 39 had KMT2A-g, who were generally older, had lower white blood cell counts, and better survival rates (6-year event-free survival of 74%).
- The findings suggest that while moderate-intensity therapy is effective, patients showing slow response to treatment may benefit from more advanced therapies like targeted or immunotherapies.
Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol.
Pediatr Blood Cancer
September 2022
Aim: The aim of the study was to evaluate the incidence and prognostic impact of central nervous system (CNS) involvement in infants with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), as well as its relation with minimal residual disease (MRD) data.
Methods: A total of 139 consecutive infants with BCP-ALL from the MLL-Baby trial were studied. Cerebrospinal fluid (CSF) samples were investigated by microscopy of cytospin slides.